This week’s topics include a comparison of abciximab and manual aspiration thrombectomy in STEMI, the quality of U.S. clinical trials, 2-year data on PARTNER, TAVR in inoperable decompensating stenosis, clopidogrel genetic testing, and strategies to reduce MI mortality.

Although two recent studies (EVA-MI and SCAAR) report that eptifibatide is as effective as abciximab with respect to myocardial reperfusion and clinical events in patients undergoing primary PCI, the thoughtful and balanced editorial accompanying them points out that the studies “ought not be considered convincing or as level 1 evidence” that the GP IIb/IIIa inhibitors…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.